Telesis Bio (NASDAQ:TBIO) Stock Price Down 2.4% – Should You Sell?

Telesis Bio, Inc. (NASDAQ:TBIO)’s stock price fell 2.4% on Thursday . The company traded as low as $0.41 and last traded at $0.41. 423 shares changed hands during trading, a decline of 92% from the average session volume of 5,125 shares. The stock had previously closed at $0.42.

Telesis Bio Trading Up 2.4 %

The firm has a market cap of $747,600.00, a price-to-earnings ratio of -0.01 and a beta of 1.64. The business’s 50-day simple moving average is $0.58 and its two-hundred day simple moving average is $2.21.

Telesis Bio (NASDAQ:TBIO) last released its earnings results on Thursday, November 7th. The company reported ($3.83) earnings per share for the quarter. The business had revenue of $1.57 million for the quarter.

Telesis Bio Company Profile

Telesis Bio, Inc, a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications.